Brief Pain Inventory (BPI)
Validated 9-item pain measure: Pain Severity (worst/least/average/current pain) and Pain Interference subscales, each 0–10. Score ≥4 indicates clinically significant pain. Cleeland & Ryan (1994). MD Anderson Cancer Center.
What is the Brief Pain Inventory?
The Brief Pain Inventory (BPI) is a validated self-report questionnaire developed by Cleeland and Ryan (1994) at the MD Anderson Cancer Center to assess the severity of pain and its impact on daily functioning. Originally developed for cancer pain research, it has since been validated across a wide range of conditions including chronic musculoskeletal pain, neuropathic pain, post-surgical pain, low back pain, and HIV-related pain. The BPI Short Form (BPI-SF) contains 9 items and takes approximately 5 minutes to complete.
The BPI has two distinct composite subscales measured on 0–10 numerical rating scales (NRS):
- Pain Severity composite — the mean of 4 items rating worst pain, least pain, average pain, and current pain ("pain right now"). Provides an overall severity score from 0 to 10.
- Pain Interference composite — the mean of 7 items rating pain interference with general activity, mood, walking ability, normal work, relations with others, sleep, and enjoyment of life. Provides an overall functional impact score from 0 to 10.
Scores of ≥4 on either subscale are commonly used to define clinically significant pain in clinical trials and practice guidelines. The BPI is free for non-commercial clinical and research use; copyright is held by Charles S. Cleeland, PhD, and the scale is administered through the Department of Symptom Research at MD Anderson Cancer Center.
BPI Score Interpreter
Enter your Pain Severity and Pain Interference composite scores (0–10) to interpret your results.
Mean of worst, least, average, current pain (0–10)
Mean of 7 interference items (0–10)
BPI-SF copyright Charles S. Cleeland, PhD. Administered by the Department of Symptom Research, MD Anderson Cancer Center. Free for non-commercial clinical use. This interpreter does not replace clinical assessment.
BPI Score Interpretation Reference
Cleeland & Ryan (1994). Severity ≥4 and/or interference ≥4 commonly defines clinically significant pain in trials and clinical guidelines. Validated in cancer, chronic, musculoskeletal, and neuropathic pain populations.
Pain Severity Scale
The Pain Severity subscale consists of 4 items, each rated 0–10 on a numerical rating scale (NRS), where 0 = "no pain" and 10 = "pain as bad as you can imagine." The composite score is the arithmetic mean of the four responses.
| Item | Prompt |
|---|---|
| Worst pain | Worst pain in the last 24 hours |
| Least pain | Least pain in the last 24 hours |
| Average pain | Average pain in the last 24 hours |
| Current pain | Pain right now |
Serlin et al. (1995) derived grading thresholds based on worst-pain ratings in cancer patients, validated by examining how each level differentially impairs functional activity, mood, and sleep. These cutpoints apply specifically to the worst-pain item rather than to the 4-item composite mean.
| Severity category | Worst-pain rating (0–10) |
|---|---|
| None | 0 |
| Mild | 1–4 |
| Moderate | 5–6 |
| Severe | 7–10 |
Tan et al. (2004) confirmed the psychometric properties of the severity subscale in 440 patients with chronic non-malignant pain (Cronbach's α = 0.85), supporting its use beyond oncology. Factor analysis consistently yields two independent factors across populations, confirming that severity and interference measure related but distinct dimensions.
Pain Interference Scale
The Pain Interference subscale consists of 7 items, each rated 0–10 (0 = "does not interfere," 10 = "completely interferes"). The composite score is the mean of all 7 responses.
Shi et al. (2017) derived empirical cutpoints for total pain interference (BPI-PITS, the mean of all 7 items) in cancer patients by pooling data from three Phase III clinical trials. Cutpoints were validated against ECOG performance status (p < 0.0001).
| Interference category | BPI-PITS composite score |
|---|---|
| Mild | < 2 |
| Moderate | 2–5 |
| Severe | > 5 |
Note: these interference cutpoints were derived in cancer populations. Their applicability to non-cancer chronic pain populations has not been as formally established; Tan et al. (2004) validated the two-factor structure in chronic non-malignant pain (α = 0.88 for interference items) but did not derive specific interference-level cutpoints for that population.
BPI Interference Items
The BPI-SF asks patients to rate how much pain has interfered with each of the following domains over the past 24 hours (or past week in some research versions), from 0 ("does not interfere") to 10 ("completely interferes"):
| # | Domain | Description |
|---|---|---|
| 1 | General activity | Day-to-day physical activity and movement |
| 2 | Mood | Emotional state and psychological wellbeing |
| 3 | Walking ability | Capacity to walk and get around |
| 4 | Normal work | Work inside and outside the home |
| 5 | Relations with other people | Social functioning and interpersonal relationships |
| 6 | Sleep | Ability to fall asleep and stay asleep |
| 7 | Enjoyment of life | Pleasure, quality of life, and positive engagement |
Shi et al. (2017) further grouped these 7 items into two subscales for research purposes: activity-related interference (BPI-WAW: work, general activity, walking — optimal cutpoints 2/6) and mood-related interference (BPI-REM: relations with others, enjoyment of life, mood — optimal cutpoints 2/5).
Pain Outcome Tracking in HiBoop
BPI alongside Pain Catastrophizing Scale, PHQ-9, and GAD-7, integrated pain and psychological outcome tracking for chronic pain, surgical, and rehabilitation patient panels.
References
- 1.Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129-138.View source
- 2.Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61(2):277-284.View source
- 3.Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133-137.View source
- 4.Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, Bhowmik D, Cleeland CS. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017;158(6):1108-1112.View source
Frequently Asked Questions
Is the BPI self-report or clinician-administered?
The BPI is a patient self-report questionnaire. The Short Form (BPI-SF) contains 9 items and takes approximately 5 minutes to complete. It can also be administered verbally or by a trained interviewer when needed.
What does a BPI score of ≥4 mean?
A composite score of ≥4 on either the Pain Severity or Pain Interference subscale is widely used in clinical trials and guidelines as the threshold for clinically significant pain. This convention originates from the WHO analgesic ladder context and is commonly applied in both cancer and chronic non-cancer pain populations.
What are the severity grading cutpoints for the BPI?
Based on Serlin et al. (1995), worst-pain ratings on the 0–10 numerical scale correspond to mild pain (1–4), moderate pain (5–6), and severe pain (7–10) in cancer patients. These cutpoints were validated by examining how worst-pain levels differentially impair functional activity, mood, and sleep. They are specific to the worst-pain item, not the 4-item composite mean.
Can the BPI diagnose a pain condition?
No. The BPI measures pain severity and functional interference — it is not a diagnostic tool for any specific pain condition. Diagnosis requires clinical evaluation, history, and appropriate investigations. The BPI is used to quantify pain burden, track outcomes over time, and support clinical decision-making.
Has the BPI been validated outside of cancer pain?
Yes. Tan et al. (2004) validated the BPI in 440 patients with chronic non-malignant pain, finding acceptable internal consistency (Cronbach's α = 0.85 for severity items, 0.88 for interference items) and a confirmed two-factor structure. It has since been validated in low back pain, osteoarthritis, neuropathic pain, Parkinson's disease, and multiple other conditions.
Related Assessments
Explore complementary clinical tools and screeners